Creative Planning Sells 1,326 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

Creative Planning reduced its position in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 7.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,442 shares of the biopharmaceutical company’s stock after selling 1,326 shares during the period. Creative Planning’s holdings in Emergent BioSolutions were worth $137,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in EBS. SG Americas Securities LLC increased its holdings in shares of Emergent BioSolutions by 250.1% during the third quarter. SG Americas Securities LLC now owns 60,724 shares of the biopharmaceutical company’s stock worth $507,000 after purchasing an additional 43,378 shares during the period. Truist Financial Corp increased its stake in Emergent BioSolutions by 12.3% during the 2nd quarter. Truist Financial Corp now owns 131,526 shares of the biopharmaceutical company’s stock worth $897,000 after acquiring an additional 14,360 shares during the period. Millennium Management LLC raised its holdings in Emergent BioSolutions by 5.8% in the 2nd quarter. Millennium Management LLC now owns 946,302 shares of the biopharmaceutical company’s stock valued at $6,454,000 after acquiring an additional 52,144 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Emergent BioSolutions during the 2nd quarter valued at $485,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Emergent BioSolutions during the 2nd quarter worth $1,576,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent BioSolutions Stock Performance

NYSE:EBS opened at $10.89 on Wednesday. Emergent BioSolutions Inc. has a twelve month low of $1.42 and a twelve month high of $15.10. The company has a quick ratio of 0.54, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The stock’s 50-day simple moving average is $8.50 and its 200 day simple moving average is $7.89. The firm has a market capitalization of $590.06 million, a PE ratio of -2.66 and a beta of 1.57.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. StockNews.com raised Emergent BioSolutions from a “hold” rating to a “buy” rating in a research note on Tuesday. Benchmark boosted their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, Rodman & Renshaw reiterated a “buy” rating and set a $16.00 price target on shares of Emergent BioSolutions in a research report on Friday, September 13th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.